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Abstract
Purpose Diabetic macular oedema (DMO) is
a leading cause of blindness in working-age
adults. Slow-release, nonbioerodible
ﬂuocinolone acetonide (FAc) implants have
shown efﬁcacy in the treatment of DMO;
however, the National Institute for Health
and Care Excellence recommends that FAc
should be used in patients with chronic DMO
considered insufﬁciently responsive to other
available therapies only if the eye to be
treated is pseudophakic. The goal of this
analysis was to examine treatment outcomes
in phakic patients who received 0.2 μg/day
FAc implant.
Methods This analysis of the phase 3 FAME
(Fluocinolone Acetonide in Diabetic Macular
Edema) data examines the safety and efﬁcacy
of FAc implants in patients who underwent
cataract extraction before (cataract before
implant (CBI) group) or after (cataract after
implant (CAI) group) receiving the implant.
The data were further examined by DMO
duration.
Results Best corrected visual acuity (BCVA)
after 36 months was comparable in the CAI and
CBI groups. Both the percentage of patients
gaining ≥3 lines of vision and mean change in
BCVA letter score were numerically greater in
the CAI group. In addition, most patients who
underwent cataract surgery experienced a net
gain in BCVA from presurgery baseline as well
as from original study baseline.
Conclusions These data support the use of
0.2 μg/day FAc implants in phakic as well as
in pseudophakic patients. These ﬁndings will
serve as a pilot for design of future studies to
evaluate the potential protective effect of FAc
implants before cataract surgery in patients
with DMO and cataract.
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Introduction
Diabetic macular oedema (DMO) is the most
common cause of vision loss in the working-age
population, and its chronic nature can
necessitate ongoing treatment to maintain
vision.1–3 Recent landmark studies have shown
that frequent intravitreal injections with
inhibitors of vascular endothelial growth factor
(VEGF) were more effective than laser
photocoagulation for the treatment of centre-
involving DMO.4–12 Despite the visual and
anatomical improvements seen in many patients
treated with anti-VEGF agents, a sizeable
proportion of patients still have a poor response,
even with frequently repeated injections. In the
phase 3 ranibizumab studies for DMO (RISE and
RIDE), between 30.4 and 43.2% of patients failed
to gain ≥ 10 letters after 3 years of treatment with
0.3 or 0.5 mg ranibizumab.4 In the Diabetic
Retinopathy Clinical Research Network
(DRCRnet) Protocol I study, at the 3-year visit,
57.6% of patients in the ranibizumab+prompt
laser group and 44.2% in the ranibizumab
+deferred laser group failed to gain ≥ 10 letters,
with 6% and 3%, respectively, losing ≥ 15
letters.5 In this study, a subanalysis showed
that ≈20% of patients could be deﬁned as
nonresponsive to ranibizumab therapy, with a
consistently o20% reduction in central retinal
thickness compared with baseline after repeated
injections over a 1-year period.13 Thus, not all
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patients with DMO experience a good and sufﬁcient
response with repeated anti-VEGF therapy.
Intravitreal steroids have been evaluated in DMO
because of their ability to act on other inﬂammatory
cytokines and pathogenetic mechanisms in addition to
those associated with VEGF. Bioerodible DEX implants
that release drug for 3 to 6 months were examined in the
PLACID and MEAD studies.14,15 The PLACID study
showed best corrected visual acuity (BCVA)
improvements (proportion of patients gaining ≥ 10 letters)
in patients with diffuse DMO treated with the DEX
implant+laser photocoagulation vs photocoagulation
alone after 9 months but did not meet its primary end
point of greater improvements at month 12.14 In the
MEAD study, the percentage of patients with 15-letter
improvement in BCVA from baseline at study end was
greater with the DEX implant 0.7 mg (22.2%) than with
sham (12.0%; P= 0.018). Rates of cataract-related adverse
events (AEs) in phakic eyes were 67.9% vs 20.4% in the
DEX implant 0.7 mg group vs sham group, respectively,
and 2 patients (0.6%) in the DEX implant 0.7 mg group
required incisional surgery for elevated intraocular
pressure.16
Slow-release, nonbioerodible implants of ﬂuocinolone
acetonide (FAc) were evaluated in patients with DMO
who had received previous laser photocoagulation in the
FAME (Fluocinolone Acetonide in Diabetic Macular
Edema) study; these implants were found to be more
efﬁcacious than the standard of care at 3 years after a
single intravitreal injection.17,18 Approximately a third
(34%) of patients with DMO for 43 years who were
treated with 0.2 μg/day FAc implant experienced a ≥ 15-
letter gain compared with 13.4% of patients treated with
sham. The results of this study led to worldwide
marketing authorizations of the 0.2 μg/day FAc implant
for the treatment of chronic DMO that has been
insufﬁciently responsive to available therapies.19
Despite the promising prospect for FAc implants to
play a major role in the long-term therapy of patients with
chronic DMO, there is still a concern over the issue of
cataract formation following intravitreal corticosteroid
therapy.18,20 This concern was reﬂected in the recent
guidance by the National Institute for Health and Care
Excellence (NICE) that FAc should be used in patients
with chronic DMO considered insufﬁciently responsive to
other available therapies only if the eye to be treated is
already pseudophakic. However, in clinical practice,
chronic DMO in phakic eyes with and without cataract is
often encountered, and the risk of developing worsening
DMO in the early postoperative period following cataract
surgery is signiﬁcantly higher, especially in patients who
had previous treatment for DMO.21–27 It is therefore of
value to investigate the outcome of FAc in phakic eyes
with chronic DMO. In this study, a post hoc analysis of
FAME study data was undertaken to evaluate the
functional and anatomical outcomes at 3 years in patients
who underwent cataract surgery during follow-up
against those who were already pseudophakic at baseline.
Materials and methods
The detailed design and methodology of the FAME study
have been described previously. Brieﬂy, the study
consisted of two phase 3, randomized, double-masked,
sham injection-controlled, parallel-group, multicentre
trials (FAME A and B; www.clinicaltrials.gov,
NCT00344968) performed under a single protocol.17,18
The trials adhered to the guidelines of the Declaration of
Helsinki and were approved by each institution’s
governing institutional review board or ethics committee.
In the FAME study, after patients with DMO gave
written informed consent, they were screened for
eligibility by having their BCVA and foveal centre point
thickness (CPT) measured, as previously described.17,18,28
Eligible patients had BCVA between 19 and 68 Early
Treatment Diabetic Retinopathy Study (ETDRS) letters
and foveal thickness ≥ 250 μm despite ≥ 1 prior focal/grid
macular laser photocoagulation treatment. Detailed
inclusion and exclusion criteria were reported
previously.17,18 A total of 956 patients were randomized
2 : 2 : 1 to treatment in a single eye with 0.2 μg/day FAc,
0.5 μg/day FAc, or sham injection (control). The full
analysis population (N= 956) consisted of all randomized
patients and was used for efﬁcacy determination. The full
safety population (n= 953) consisted of all patients
receiving ≥ 1 study treatment; prespeciﬁed subgroups
were examined to determine whether certain patient
populations had an expanded beneﬁt-to-risk ratio.
Subgroup populations presented herein (chronic and
nonchronic DMO) consisted of all patients with a
duration of DMO ≥ oro the median duration of all study
participants, respectively. The median baseline duration
of DMO in the FAME study, as calculated by the
prespeciﬁed algorithm ((year of randomization)− (year of
diagnosis)+1), was 3 years. This was the prespeciﬁed
algorithm to determine median duration of DMO at
baseline; however, the robustness of this ﬁnding was
tested with a sensitivity analysis exploring the differential
treatment effect when the duration of DMO was
calculated using the day/month/year for diagnosis and
randomization. This yielded a median DMO duration of
1.73 years. Because the differential treatment effect seen
with the preplanned algorithm was replicated, with the
algorithm providing a more exact determination of
median duration of DMO at baseline (κ= 0.8508), results
in the present analysis used the prespeciﬁed algorithm,
yielding a median DMO of 3 years.
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Timing of study visits was presented previously.17,18
Lens status was determined by the assessing physician
before randomization. Patients underwent cataract
surgery by phacoemulsiﬁcation technique at the
discretion of the masked investigator. No guidance was
given regarding the timing of cataract surgery.
In this post hoc analysis, only patients treated with
0.2 μg FAc were included, as the number of patients
treated with sham injections undergoing cataract surgery
was small (n= 32).
Statistical analyses
Patients were initially divided into two main subgroups
according to whether their study eye underwent cataract
extraction before (cataract before implant (CBI) group) or
after (cataract after implant (CAI) group) receiving the
implant. Each subgroup was then subdivided into two
further subgroups according to whether the duration of
DMO in the study eye was o3 years (nonchronic) or
≥ 3 years (chronic).
Comparisons were not tested for signiﬁcance because
of the post hoc nature of the analyses. Efﬁcacy and safety
after cataract surgery were run as observed case analyses,
using only data available at the observed time points
without imputing any values for missing patient data.
Changes in visual acuity were summarized relative to the
last presurgical assessments to characterize the effects
of cataract surgery. Other outcomes included foveal
thickness changes, ﬂuorescein leakage, and AEs following
cataract surgery that were observed during the FAME
study follow-up period.
Results
Demographics
In the FAME trials, 956 patients in the full safety
population were randomized to either 0.2 μg/day FAc
(n= 376), 0.5 μg/day FAc (n= 395), or sham injection
(control; n= 185) in one study eye (Figure 1). The mean
age of the FAME trial population was 62.5 years. Among
those receiving 0.2 μg/day FAc, 328 patients were
pseudophakic; of these, 140 had cataract surgery before
receiving the FAc implant (CBI group) and 188 had
cataract surgery after receiving the implant (CAI group).
The mean age of patients receiving cataract surgery before
receiving the implant (CBI group) was 67.7; mean age for
patients receiving cataract surgery after receiving the
implant (CAI group) was 60.5 years, respectively
(Po0.0001). The baseline characteristics in terms of
BCVA, CPT, duration and type of diabetes, and
glycosylated haemoglobin were similar across all four
subgroups (Table 1). In the CBI group, median time to
development of cataract was 12 months; median time to
cataract extraction was 18 months.
Visual acuity outcomes
When all patients treated with 0.2 μg/day FAc were
examined, visual acuity after 36 months was comparable
in patients who had cataract surgery after (CAI group)
and in those who had cataract surgery before (CBI group)
receiving the implant.
Visual outcome (the proportion of patients who
experienced a ≥ 15-letter improvement) at month 36 was
slightly higher overall in the CAI group (35.1%) than in
the CBI group (29.3%; Figure 2a). When the change in
BCVA letter score from baseline to month 36 was
considered, patients in the CAI group experienced a
decline in BCVA between months 6 and 18 as expected
because of cataract formation. Patients in the CBI group
did not experience this dip and maintained their visual
gain from month 3 (Figure 2b). However, at 36 months,
the change in BCVA was numerically greater in the CAI
group. Of note, most pseudophakic patients enrolled in
the FAME trials had undergone cataract surgery
49 months before randomization, a time considered long
enough for inﬂammation because of cataract surgery to
resolve. When BCVA outcome was analysed as a function
of time in patients whose cataract surgery occurred within
9 months vs outside this window, no signal was seen that
would support an increased effect in patients whose
surgery occurred closer to randomization.
When only patients who had cataract surgery during
the study (CAI group) were evaluated, patients with
chronic DMO were more likely to gain a ≥ 15-letter
improvement than those with nonchronic DMO (42.3% vs
27.5%, respectively; Figure 3a). Improvements in mean
BCVA letter score were also greater in chronic vs
nonchronic patients (11.1 vs 4.3 letters, respectively;
Figure 3b).
The visual gain in patients with chronic DMO in the
CAI group can also be illustrated individually using a
waterfall plot, as shown in Figure 4. The majority of
patients who underwent cataract surgery experienced a
net gain in BCVA from presurgery baseline (measured at
the last time point directly preceding surgery; Figure 4a).
The maximum gain among these patients was +77 letters
and the maximum loss was − 14 letters. Vision
improvement was also noted after cataract surgery
relative to original study baseline, as shown in Figure 4b.
Angiographic and morphological changes
For the full population, the change from baseline in
ﬂuorescein leakage at month 36 was similar between CBI
and CAI patients (−2.1 and − 1.7 disc areas, respectively).
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Moreover, values were similar regardless of DMO
chronicity. Among CBI patients with chronic DMO, the
change from baseline was − 2.0 disc areas vs − 2.4 disc
areas for CBI patients with nonchronic DMO. Among CAI
patients, the change in ﬂuorescein leakage at month 36
slightly favoured chronic vs nonchronic patients (−2.1 vs
− 1.3 disc areas). When these anatomical outcomes
following cataract surgery in CAI patients treated with
0.2 μg/day FAc were examined speciﬁcally, there was an
increase in ﬂuorescein leakage at 6 months post procedure
(1.21 disc areas); this was reduced to a 0.55–disc area
increase at 12 months post procedure from presurgery
baseline. In contrast, ﬂuorescein leakage remained
relatively constant for patients receiving sham at 6 and
12 months post procedure (2.4 and 2.37 disc areas,
respectively).
In addition, in patients treated with 0.2 μg/day FAc
who underwent cataract surgery, CPT showed a small
increase immediately after surgery that quickly recovered
by month 3 and was stable to month 12 in patients with
chronic DMO (mean CPT of 287 μm at the last visit before
cataract surgery; 365 μm at 1 month post surgery; 297 μm
at 3 months post surgery). In patients with nonchronic
DMO, the stabilization did not occur until month 9 (mean
CPT of 308 μm at the last visit before cataract surgery;
355 μm at 1 month post surgery and returned to
presurgery values by month 9 (312 μm). These ﬁndings
suggest that macular anatomy was not disturbed
following cataract surgery, especially in patients with
chronic DMO who had received 0.2 μg/day FAc.
AEs after cataract surgery
AEs were uncommon following cataract surgery. Corneal
oedema—which occurred in 7 of 188 patients (3.7%) in the
0.2 μg/day FAc implant group, 8 of 231 (3.5%) in the
All randomized
(N = 956)
Sham control
(n = 185)
CAI:
Cataract (surgery)
after implant
(n = 32)
CBI:
Cataract (surgery)
before implant
(n = 64)
Phakic at all
times
(89)
Not included
in analysis
CAI:
Cataract (surgery)
after implant
(n = 188)
Phakic at all
times
(n = 48)
CBI:
Cataract (surgery)
before implant
(n = 140)
0.2 µg/d FAc
(n = 376)
0.5 µg/d FAc
(n = 395)
Not included
in analysis
Not included
in analysis
(1 with unknown DMO duration)
Nonchronic
(n = 44)
Chronic
(n = 95)
Nonchronic
(n = 91)
Chronic
(n = 97)
Figure 1 Flow-through study by lens status and duration of DMO. DMO, diabetic macular oedema; FAc, ﬂuocinolone acetonide.
Table 1 Baseline characteristics of 0.2 μg/day FAc-treated patients by lens status and duration of DMO
Pseudophakic at baseline (CBI group) Phakic→ pseudophakic (CAI group)
Chronic DMO
(n= 95)
Nonchronic DMO
(n= 44)
Chronic DMO
(n= 97)
Nonchronic DMO
(n= 91)
BCVA, mean (SE), ETDRS letters 52.5 (1.40) 53.3 (2.00) 51.6 (1.33) 54.7 (1.19)
Centre point thickness, mean (SE), μm 448.0 (17.45) 490.0 (22.59) 462.0 (17.11) 463.2 (16.43)
Duration of diabetes, mean (SE), y 19.7 (0.98) 18.2 (1.54) 17.2 (0.93) 15.0 (0.91)
Duration of DMO, mean (SE), y 5.1 (0.31) 1.6 (0.08) 5.2 (0.33) 1.7 (0.05)
Diabetes type, n (%)
Type 1 8 (8.4) 3 (6.8) 9 (9.3) 4 (4.4)
Type 2 85 (89.5) 41 (93.2) 85 (87.6) 86 (94.5)
Uncertain 2 (2.1) 0 3 (3.1) 1 (1.1)
HbA1c, mean (SE), % 7.6 (0.16) 7.8 (0.17) 7.9 (0.17) 7.9 (0.19)
Abbreviations: BCVA, best corrected visual acuity; CAI, cataract (surgery) after implant; CBI, cataract (surgery) before implant; DMO, diabetic macular
oedema; ETDRS, Early Treatment Diabetic Retinopathy Study; FAc, ﬂuocinolone acetonide; HbA1c, glycosylated haemoglobin; SE, standard error.
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0.5 μg/day FAc implant group, and 0 of 33 in the sham
control group—was transient and mild. Among patients
receiving 0.2 μg/day FAc who underwent laser
capsulotomy, 9 of 11 had postcapsulotomy follow-up
ranging from 197 to 666 days, with 2 patients
undergoing the procedure just before exiting the study.
Of the 9 patients with long-term follow-up, no migration
of the implant into the anterior chamber was reported.
All other events studied—including wound dehiscence,
cataract operation complication, eye inﬂammation, and
anterior chamber ﬂare—occurred in two or fewer
patients.
Discussion
The FAc implant was found to be cost effective by NICE
in patients with chronic DMO considered insufﬁciently
responsive to other therapies, provided the eye to be
treated was already pseudophakic. The reason for the
stipulation on the pseudophakic status of the treated eye
was because of differences in cost effectiveness between
treating phakic and pseudophakic eyes.29 Although this
guidance has been very helpful for the clinician who is
faced with a patient whose DMO has been unresponsive
Figure 3 Visual acuity in 0.2 μg/day FAc-treated patients who
developed cataract during the FAME trials (CAI group).
(a) Proportion of patients experiencing a ≥ 15-letter improvement
in BCVA and (b) mean change in BCVA letter score. BCVA, best
corrected visual acuity; CAI, cataract (surgery) after implant; CBI,
cataract (surgery) before implant; FAc, ﬂuocinolone acetonide;
FAME, Fluocinolone Acetonide in Diabetic Macular Edema.
Figure 4 Change in visual acuity following cataract surgery in
0.2 μg/day FAc-treated patients with chronic DMO (a) from the
last presurgical BCVA letter score to the last postsurgical BCVA
letter score and (b) from original study baseline to the last
postsurgical BCVA letter score. BCVA, best corrected visual
acuity; DMO, diabetic macular oedema; ETDRS, Early Treatment
Diabetic Retinopathy Study; FAc, ﬂuocinolone acetonide. Black
lines indicate improvement of ≥ 15 letters.
Figure 2 Visual acuity in 0.2 μg/day FAc-treated patients as
a function of lens status. (a) Proportion of patients experiencing a
≥ 15-letter improvement in BCVA and (b) mean change in BCVA
letter score. BCVA, best corrected visual acuity; CAI, cataract
(surgery) after implant; CBI, cataract (surgery) before implant;
FAc, ﬂuocinolone acetonide. aIntegrated full analysis population.
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to other therapies, it has also resulted in an unmet need
for patients with chronic DMO who are phakic, with or
without cataract. In addition, it has raised the question of
whether it is actually less clinically beneﬁcial to use FAc
in phakic eyes and then perform cataract surgery
subsequently if and when the cataract worsens or
develops. The FAME study is the largest study to date on
the treatment of DMO using the 0.2 μg/day FAc
implant. Given the comparable numbers of patients
who were phakic and pseudophakic at baseline and the
availability of long-term prospective follow-up data,
the study provides a useful opportunity to compare
long-term outcomes of patients with DMO undergoing
cataract surgery after implantation (CAI) with those
undergoing cataract surgery before implantation
(CBI). Results in patients who had cataract surgery
during the FAME trials showed that visual outcomes of
phakic eyes treated with 0.2 μg/day FAc were no worse
and possibly better than visual outcomes seen in
patients with pseudophakic eyes. When postcataract
surgery outcomes in patients who had surgery during
the study were examined, these ﬁndings suggest a
possible protective effect of following treatment with
0.2 μg/day FAc on macular function in eyes that have
to undergo cataract surgery.
Cataract occurred at an expectedly high rate in phakic
patients treated with the FAc implant, as this is a known
effect of any intravitreal corticosteroid therapy. However,
in contrast to previous reports that have demonstrated an
exacerbation of DMO and worsening of vision following
cataract extraction in this population, the results from this
post hoc analysis suggest that visual outcomes in these
patients were not negatively affected by cataract surgery.
Among patients receiving 0.2 μg/day FAc implants, more
phakic patients who underwent cataract surgery during
the study experienced numerically higher gains in mean
BCVA and a ≥ 15-letter improvement than those who
were pseudophakic at baseline. This differential in visual
acuity outcome was even more pronounced in patients
with chronic DMO.
When outcomes following cataract surgery were
examined, patients treated with 0.2 μg/day FAc
implants experienced an increase in BCVA following
surgery that continued for 1 year. This is in contrast to
reports that patients with more advanced DMO
experience poor visual outcomes after cataract
surgery.25,26,30–32 Overall, these ﬁndings suggest that the
continuous exposure of low-dose corticosteroid
provided by 0.2 μg/day FAc implants may provide a
protective effect in the period directly following and/or
during cataract surgery as well as favourable long-term
visual outcomes.
It has been reported that inﬂammatory factors are
upregulated after cataract extraction, the presence of
which could contribute to worsening of DMO and
decreased vision.22,33 A low dose of corticosteroid present
during and after surgery could ameliorate this inﬂux of
inﬂammatory factors and associated sequelae that in turn
may account for some of the differences seen between the
0.2 μg/day FAc group and sham control group. Because
some retina specialists may delay cataract surgery in
patients with DMO based on the potential for
exacerbation, the presence of 0.2 μg/day FAc implant
may inﬂuence clinical behaviour. The protective effect
noted among patients treated with 0.2 μg/day FAc
implants who underwent cataract surgery and the vision
gains noted among those who became pseudophakic with
an implant in the eye may therefore support the
implantation of this device in patients with chronic DMO
regardless of lens status. Of importance is the observation
that in patients treated with the 0.2 μg/day FAc implant
who underwent cataract surgery and subsequent
capsulotomy, there was no evidence of migration of the
implant into the anterior chamber.
One of the limitations of this study was the post hoc
nature of the analyses. As such, these results were not
powered to detect differences between patients receiving
sham and those treated with 0.2 μg/day FAc. The
observed case analysis of the postcataract surgery
mean change in BCVA favoured the 0.2 μg/day FAc-
treated patients. However, there was a signiﬁcant
difference in the age of participants in the CAI and
CBI groups that could have affected the results and
this underscores the need for prospective study on
this topic. It is also important to note that the majority
of patients in the FAME study were probably
already presbyopic at baseline and would not have lost
accommodative function as a result of cataract
surgery. For younger patients with chronic DMO
who still have natural accommodative power and no
cataract formation or symptoms, it may be more
appropriate to defer 0.2 μg/day FAc intravitreal
implant until it is clear that an adequate response
with anti-VEGF therapy cannot be achieved.
In conclusion, these data support the use of 0.2 μg/day
FAc implants in both pseudophakic and phakic eyes of
patients with chronic and nonchronic DMO. Phakic eyes
with chronic DMO treated with FAc and requiring
subsequent cataract surgery had particularly favourable
visual outcomes. These ﬁndings will be of value to clinicians
in justifying the use of FAc in phakic eyes of patients with
DMO that has been unresponsive to other therapies and will
serve as a pilot for the design of future studies to evaluate
whether there is any protective effect of a FAc implant
before cataract surgery in patients with DMO and cataract.
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Summary
What was known before
K One treatment option for DMO is slow-release,
nonbioerodible FAc implants that have been shown to be
efﬁcacious but have a well-documented AE proﬁle that
includes cataract formation.
K In the United Kingdom, NICE recommends the use of FAc
implants in patients with chronic DMO considered
insufﬁciently responsive to other available therapies only
if the eye to be treated is pseudophakic.
What this study adds
K This study compared outcomes of patients who started the
FAME trials as pseudophakic with outcomes of patients
who underwent cataract surgery after receiving a FAc
implant. Outcomes following cataract surgery in patients
who received a FAc implant were also evaluated.
K Results demonstrated that patients who had cataract
surgery after receiving 0.2 μg/day FAc implant
experienced long-term outcomes that were no worse and
possibly better than outcomes observed in pseudophakic
patients who also received 0.2 μg/day FAc implant.
K When postcataract surgery outcomes in patients who
received 0.2 μg/day FAc implant were evaluated, a
possible protective effect on postcataract surgery outcomes
following treatment with 0.2 μg/day FAc was suggested.
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